

Date: 12 February 2020

Re: Freedom of Information Request
Ref: 17 - 2020

Thank you for your email dated the 16th January 2020, requesting information regarding patient treatment figures.

The information that you require is as follows:

Please note in accordance with the Data Protection Act 2018 our Trust is unable to release all of the information requested. The Clatterbridge Cancer Centre NHS Foundation Trust (CCC) is a relatively small Trust and by providing this level of detail where the number of patients is less than or equal to five increases any 'potential' risk of this data becoming identifiable information and thereby contravening one or more of the Data Protection Principles by releasing it into the public domain. Confidentiality is expected in such matters. This information is therefore exempt under Section 40: Personal Information, of the Freedom of Information Act 2000. The areas where this exemption has been applied are shown below:

1. **Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma)?**

229

2. **Of these patients how many are locally advanced and how many are recurrent and/or metastatic head and neck cancer patients?**

Locally advanced

Recurrent metastatic

Unknown

Information not held- The Clatterbridge Cancer Centre only collect staging at presentation, this information is therefore not held within our systems.

3. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma) with the following agents?

July – December 2019

Carboplatin (only or in combination with 5-FU)	8
Cisplatin (only or in combination with 5-FU)	12
Cetuximab with/without chemotherapy	Exempt under S.40
Cetuximab with radiotherapy	Exempt under S.40
Pembrolizumab monotherapy	0
Pembrolizumab with chemotherapy	0
Nivolumab	25
Docetaxel (only or in combination with 5-FU)	0
Fluorouracil (5FU)	0
Radiotherapy only	115
Other	66

Does your health trust participate in any ongoing clinical trials for the treatment of head and neck cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?

July – December 2019

COMPARE	Exempt under S.40
JAVELIN	Exempt under S.40
NICO	6
PATHOS	6

4. Within your health trust how many patients have been treated in the past 6 months with the following agent for colorectal cancer [CRC];

July – December 2019

Aflibercept	0
Bevacizumab	0
Capecitabine	53
CAPIRI	33
CAPOX	156
Cetuximab not in combination with FOLFIRI or FOLFOX	19
Cetuximab in combination with FOLFIRI	Exempt under S.40
Cetuximab in combination with FOLFOX	Exempt under S.40
Irinotecan	21
FOLFIRI	86
FOLFOX	140
Oxaliplatin	Exempt under S.40
Panitumumab not in combination with FOLFIRI or FOLFOX	Exempt under S.40
Panitumumab in combination with FOLFIRI	Exempt under S.40
Panitumumab in combination with FOLFOX	Exempt under S.40
Nivolumab	0
Raltitrexed	0
Ramucirumab	0
Regorafenib	0
Sorafenib	0
5FU only	43
Tegafur Uracil + 5FU	0
Trifluridine–tipiracil	18
XELOX	As above (CAPOX)

Other	70
-------	----

5. Within your health trust how many patients have been treated in the past 6 months with the following agent for Renal Cell Carcinoma:
July – December 2019

Sunitinib	9
Avelumab + Axitinib	6
Axinitib	Exempt under S.40
Cabozantinib	24
Everolimus	0
Lenvantinib + Everolimus	0
Nivolumab	22
Nivolumab + Ipilimumab	37
Pazopanib	11
Pembrolizumab + Axitinib	0
Sunitinib	9
Temsirolimus	0
Tivozanib	22

6. Does your health trust participate in any ongoing clinical trials for the treatment of renal cell cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?

July – December 2019

EV301	Exempt under S.40
PRISM	21
RAMPART	Exempt under S.40
STAR	Exempt under S.40
WO29637	Exempt under S.40

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

<https://www.surveymonkey.co.uk/r/H39RFMM>